Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 May 2024Published: 28 May 2014
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 May 2024Published: 19 December 2019
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 May 2024Published: 22 August 2007
Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2022
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 June 2021
Ofatumumab for treating relapsing multiple sclerosis (TA699)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Siponimod for treating secondary progressive multiple sclerosis (TA656)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 November 2020
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 February 2020
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 June 2019
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 July 2018
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2018
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 August 2014
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 June 2014Published: 22 January 2014
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 April 2012
Cladribine for treating relapsing multiple sclerosis [ID6263]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 February 2025
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 July 2025
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Glatiramer acetate depot for multiple sclerosis [TS ID 10620]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ublituximab for treating relapsing multiple sclerosis [ID6350]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tolebrutinib for treating relapsing multiple sclerosis ID6351Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Evobrutinib for treating relapsing multiple sclerosis [ID6313]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC